drugset / Trial / NCT05878691
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Non-randomizedSequentialOpen-labelTreatment
Summary
This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or atezolizumab in participants with advanced solid tumors and lymphomas.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2027-07-30
- Completion
- 2027-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | GRC 54276 | Unknown | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |